Today: 7 February 2026
Subscribe
Browse Category

NYSE:ABBV News 26 January 2026 - 6 February 2026

AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt

AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt

AbbVie shares climbed 2% to $223.45 in midday trading Friday after a volatile week. The move followed a quarterly report showing fourth-quarter net revenues up 10% to $16.62 billion and adjusted profit of $2.71 per share. Humira sales dropped 25.9% as biosimilar competition increased, while Skyrizi and Rinvoq posted gains. The company also announced new regulatory approvals and licensing deals.
6 February 2026
···
AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss

AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss

AbbVie shares rose 0.7% to $219.02 in after-hours trading Thursday, rebounding after a nearly 6% drop following its earnings report. Skyrizi beat sales estimates with $5.01 billion, while Rinvoq missed at $2.37 billion. The company raised its 2026 forecast for the pair to $31.6 billion. Investors remain focused on whether new drugs can offset Humira’s ongoing decline.
6 February 2026
···
AbbVie stock slides after earnings: Rinvoq miss dents ABBV despite upbeat 2026 view

AbbVie stock slides after earnings: Rinvoq miss dents ABBV despite upbeat 2026 view

AbbVie shares fell 3.9% in after-hours trading Wednesday after quarterly results showed Rinvoq sales missed expectations at $2.37 billion. Skyrizi sales beat forecasts at $5.01 billion, while Humira revenue dropped 25.9% to $1.25 billion. The company projected 2026 adjusted earnings above estimates, but investors focused on challenges replacing Humira as biosimilar competition grows.
5 February 2026
···
AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates

AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates

AbbVie shares fell 2.5% to $219.98 Wednesday after Rinvoq sales missed forecasts, despite the company raising its 2026 profit outlook. Q4 adjusted earnings reached $2.71 per share on $16.618 billion revenue; Skyrizi sales rose 32.5%, while Humira dropped 25.9%. AbbVie announced a three-year Medicaid pact with the Trump administration and pledged $100 billion in U.S. investments.
4 February 2026
···
AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next

AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next

AbbVie shares rose 0.8% to $227.55 Tuesday afternoon ahead of its quarterly earnings report due Wednesday morning. The company filed with U.S. and European regulators to expand Rinvoq’s use to non-segmental vitiligo, based on Phase 3 data. Investors are watching whether new immunology drugs can offset Humira’s sales decline.
3 February 2026
···
AbbVie stock gains ahead of earnings; ABBV investors brace for guidance and a $1.3 billion expense

AbbVie stock gains ahead of earnings; ABBV investors brace for guidance and a $1.3 billion expense

New York, February 2, 2026, 16:10 (EST) — After-hours trading AbbVie shares climbed $2.69, or 1.2%, on Monday, settling at $225.70 after hitting a session high of $229.80. AbbVie is set to release full-year and fourth-quarter earnings on Wednesday. Investors will be watching to see if its newer products can step up as Humira’s sales decline amid growing competition from generics. This is crucial now since the stock can’t afford to wander. Investors demand the numbers first, then the outlook — and both need to meet the high expectations already established in large-cap healthcare. Monday’s market moved more quietly, with
2 February 2026
···
AbbVie stock rises into weekend as Feb. 4 earnings loom — what traders watch next

AbbVie stock rises into weekend as Feb. 4 earnings loom — what traders watch next

AbbVie shares closed Friday at $223.01, up 1.2%, outpacing big pharma peers as trading volume topped its 50-day average. The company reports earnings Wednesday, with analysts watching Skyrizi, Rinvoq, and the aesthetics segment. AbbVie’s full-year adjusted earnings guidance stands at $9.90 to $9.94. Investors remain cautious amid macroeconomic uncertainty and upcoming U.S. jobs data.
1 February 2026
··
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer shares fell 1.8% to $26.02 after U.S. Medicare included Xeljanz in its upcoming drug price negotiations, set to begin in 2026 with prices effective in 2028. The Centers for Medicare & Medicaid Services named 15 drugs for talks, and companies must decide by February 28 whether to participate. Investors are awaiting Pfizer’s February 3 earnings for updates on pricing risks.
28 January 2026
······
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
·······
AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie shares closed up 0.7% at $220.77 on Monday, moving with broader Wall Street gains ahead of the Federal Reserve’s policy decision and major tech earnings. The company will report full-year and Q4 results before the market opens on Feb. 4. AbbVie recently signed a $650 million cancer drug licensing deal with RemeGen and faces investor scrutiny over its post-Humira growth strategy.
27 January 2026
···
AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie shares rose 0.4% to $220.10 Monday, moving between $217.15 and $221.48 as investors awaited its Feb. 4 earnings report. Health-care stocks held firm, with the sector ETF up 0.4% and Johnson & Johnson and Pfizer also gaining. AbbVie’s upcoming results will highlight its immunology drugs as it faces pressure from declining Humira sales and recent policy deals. Traders are watching Wednesday’s Fed decision before the earnings release.
26 January 2026
···
1 2 3 … 7

Stock Market Today

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop